CellSeed

CellSeed Operating Expenses

The Total Operating Expenses of CellSeed (7776.T) as of Nov 11, 2026 is 720.05 M JPY. In the previous year, Total Operating Expenses was 573.32 M JPY — a change of 25.59% (higher).

Operating Expenses

720.05 MJPY

YoY

25.59%

Last updated:

Total Operating Expenses of CellSeed is 2025 720.05 M JPY. Total Operating Expenses of CellSeed was 2024 573.32 M JPY. It decreases by 25.59% higher compared to the previous year.

The CellSeed Operating Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Expenses
Date
Operating Expenses
Jan 1, 2018
823.63 M JPY
Jan 1, 2019
653.36 M JPY
Jan 1, 2020
501.84 M JPY
Jan 1, 2021
599.24 M JPY
Jan 1, 2022
804.23 M JPY
Jan 1, 2023
456.41 M JPY
Jan 1, 2024
573.32 M JPY
Jan 1, 2025
720.05 M JPY
The CellSeed Operating Expenses history
YEAROperating ExpensesYoY
720.05 MJPY+25.59%
573.32 MJPY+25.61%
456.41 MJPY-43.25%
804.23 MJPY+34.21%
599.24 MJPY+19.41%
501.84 MJPY-23.19%
653.36 MJPY-20.67%
823.63 MJPY-19.75%
1.03 BJPY-28.65%
1.44 BJPY+116.29%
665.00 MJPY+15.45%
576.00 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CellSeed Stock analysis

What does CellSeed do? CellSeed Inc. generates revenue through two primary business segments. The Regenerative Medical Support segment sells temperature-responsive cell incubators developed by the company. These incubators are used in medical research and treatment applications. The Cell Sheet Regeneration Medical segment focuses on developing cell sheet regenerative medical products for therapeutic use. Both segments contribute to the company's revenue streams through product sales and research activities. The company serves medical institutions and research organizations requiring advanced regenerative medicine solutions. The Regenerative Medical Support segment's products are specifically designed for temperature-responsive cell culture applications. These incubators support cell growth and maintenance in controlled environments. The Cell Sheet Regeneration Medical segment's products involve innovative cell sheet technologies for tissue regeneration. These products are targeted at medical professionals and research facilities seeking advanced regenerative treatments. The company's focus on regenerative medicine positions it within the healthcare technology sector. CellSeed Inc. develops and sells its own proprietary products without external branding. The temperature-responsive cell incubators and cell sheet regenerative medical products are the company's core offerings. The company's business model relies on direct sales of these products to medical and research institutions. The products are sold under the company's own brand name without third-party branding. CellSeed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CellSeed stock

Total Operating Expenses of CellSeed is 720.05 M JPY in 2025.

Total Operating Expenses of CellSeed changed from 573.32 M JPY to 720.05 M JPY, representing a 25.59% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Operating Expenses CellSeed since 2006 – with annual values, charts, and detailed analysis.

Operating expenses are the costs incurred in the normal course of business operations, including COGS, SG&A, R&D, and depreciation.

Total Operating Expenses's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Operating Expenses's CellSeed historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — CellSeed

All Key Metrics — CellSeed